Literature DB >> 18953387

Has the prevalence and severity of symptoms of asthma changed among children in New Zealand? ISAAC Phase Three.

M Innes Asher1, Alistair W Stewart, Tadd Clayton, Julian Crane, Philippa Innes Ellwood, Richard Mackay, Ed Mitchell, Chris Moyes, Philip K Pattemore, Neil Pearce.   

Abstract

AIM: To investigate time trends in prevalence of symptoms of asthma by repeating, during 2001-3 (Phase Three), the International Study of Asthma and Allergies in Childhood (ISAAC) Phase One study that was conducted in New Zealand in 1992-3.
METHODS: ISAAC Phase Three involved repeating the cross-sectional questionnaire survey of two age groups of school children (6-7 years and 13-14 years, children and adolescents respectively) using the same methodology as Phase One. In New Zealand it was conducted in Auckland, Bay of Plenty, Christchurch, Nelson, and Wellington.
RESULTS: After 9 years, reported asthma ever increased from 24.6% to 30.2% in children and from 24.1% to 32.4% in adolescents (p<0.001). Current wheeze (written questionnaire) significantly decreased in children from 23.6% to 22.2% (p=0.002) and in adolescents from 29.7% to 26.7% (p=0.047), and for the video questionnaire from 18.1% to 11.1% (p<0.001). There was a significant reduction in wheezing limiting speech from 5.0% to 3.7% in children, and 7.9% to 6.2% in adolescents. Little regional variation was found. A higher proportion of children with asthma symptoms now report having ever had asthma.
CONCLUSIONS: The decrease in prevalence and severity of symptoms of asthma is encouraging, but the reasons for these trends are currently unclear. Increases in asthma labelling are likely to be due to greater awareness of asthma. A trend of decreasing prevalence of asthma symptoms, if maintained, has positive implications for lessened burden of disease among asthmatics and lowered cost of treatment.

Entities:  

Mesh:

Year:  2008        PMID: 18953387

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  5 in total

1.  Analysis of total immunoglobulin E and specific immunoglobulin E of 3,721 patients with allergic disease.

Authors:  Man-Li Chang; Can Cui; Yan-Hong Liu; Li-Chun Pei; Bing Shao
Journal:  Biomed Rep       Date:  2015-04-29

2.  Asthma in an urban population in Portugal: a prevalence study.

Authors:  Jaime Correia de Sousa; Maria Espírito Santo; Tânia Colaço; Filipa Almada-Lobo; John Yaphe
Journal:  BMC Public Health       Date:  2011-05-19       Impact factor: 3.295

3.  Randomised controlled trial of paracetamol or ibuprofen, as required for fever and pain in the first year of life, for prevention of asthma at age 6 years: paracetamol or ibuprofen in the primary prevention of asthma in Tamariki (PIPPA Tamariki) protocol.

Authors:  Eunicia Tan; Irene Braithwaite; Christopher McKinlay; Judith Riley; Karen Hoare; Karaponi Okesene-Gafa; Alex Semprini; Nicolette Sheridan; Cameron Grant; David Johnson; Mark Weatherall; Innes Asher; Richard Beasley; Stuart R Dalziel
Journal:  BMJ Open       Date:  2020-12-10       Impact factor: 2.692

4.  An indigenous approach to explore health-related experiences among Māori parents: the Pukapuka Hauora asthma study.

Authors:  Bernadette Jones; Tristram R Ingham; Fiona Cram; Sarah Dean; Cheryl Davies
Journal:  BMC Public Health       Date:  2013-03-15       Impact factor: 3.295

5.  Ethnic disparities in asthma treatment and outcomes in children aged under 15 years in New Zealand: analysis of national databases.

Authors:  Todd D Gillies; Andrew M Tomlin; Susan M Dovey; Murray W Tilyard
Journal:  Prim Care Respir J       Date:  2013-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.